BUYSELL, trials, and more

<141A> Trial Co. upwardly revised its forecast for the current fiscal year's operating profit to JPY 28.00 billion from JPY 25.40 billion. <196A> MFS upwardly revised its forecast for the current fiscal year's operating profit to JPY 200 million from JPY 195 million. <246A> Asa Co. has revised its shareholder benefits program. <269A> Sapeet Co. upwardly revised its forecast for the current fiscal year's operating profit to JPY 120 million from JPY 82 million. <2986> LAHD Co. has introduced a shareholder benefits program and implemented a stock split, increasing from 1 share to 3 shares. The interim dividend at the end of the second quarter has been raised to JPY 177.00 per share from JPY 175.00. <378

Fisco JapanMay 14 18:30 ET

Anges --- Q1 revenue increased by double digits, with steady progress in the entrustment of expanded newborn screening and the progeria treatment drug 'Zokinvy.'

Anges <4563> announced its consolidated financial results for the first quarter of the fiscal year ending December 2026 (January to March 2026) on the 8th. Revenue increased by 20.4% year-over-year to 203 million yen, while operating loss amounted to 1.496 billion yen (compared to a loss of 1.255 billion yen in the same period last year), ordinary loss was 1.110 billion yen (versus a loss of 1.237 billion yen previously), and the net quarterly loss attributable to parent company shareholders was 1.082 billion yen (compared to a loss of 1.247 billion yen last year). The company group markets Zokinvi, a drug for the treatment of progeria.

Fisco JapanMay 10 21:35 ET

Two companies have disclosed their reports, and one has postponed—first and third quarter earnings announcements on August 8 under the going concern assumption.

In the earnings briefings for the first and third quarters disclosed on May 8, two listed companies included a note regarding the going concern assumption due to the existence of events or conditions that raise significant doubt about their ability to continue as a going concern. The companies in question are as follows: ▽ Fiscal year ending December 2026, First Quarter <4563> AnGes, <4572> Carna Biosciences. Additionally, while there were events or conditions that raised significant doubt, it was determined that substantial uncertainties related to the going concern assumption were alleviated through resolution or improvement measures.

Jiji PressMay 10 21:12 ET

Nintendo reported a 27.5% increase in full-year operating profit to 360.1 billion yen for the fiscal year ending March 26, and forecasts a 2.7% increase to 370 billion yen for the next fiscal year ending March 27.

Nintendo <7974> reported consolidated results for the fiscal year ending March 2026, with net sales increasing 98.6% year-on-year to 2.313051 trillion yen and operating income rising 27.5% to 360.117 billion yen. The launch of "Poco a Pokemon" in March contributed significantly to hardware sales, bringing total unit sales for the fiscal year to 19.86 million units. Meanwhile, the Nintendo Switch, which marked its 10th anniversary in March, continued to see steady demand, with hardware unit sales reaching 3.8 million units.

Fisco JapanMay 10 17:17 ET

AnGes 1Q Loss Y1.08B Vs Loss Y1.25B

Dow JonesMay 8 03:01 ET

AnGes: First Quarter Earnings Release for the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)

JPXMay 8 03:00 ET · Announcements